Clinical TrialMay 27, 2026, 09:07 AM
MetaVia DA-1726 Phase 1 Data Shows 9.1% Weight Loss at Day 54
AI Summary
MetaVia Inc. announced new Phase 1 data for DA-1726, a dual GLP1R/GCGR agonist, presented at EASL 2026. The 48 mg cohort demonstrated favorable safety and tolerability, achieving up to 9.1% mean body weight reduction at Day 54 without titration. Exploratory FibroScan assessments also indicated early liver-related improvements, supporting its potential in obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company is continuing Phase 1 titration studies to evaluate longer-term dosing strategies.
Key Highlights
- DA-1726 showed up to 9.1% mean body weight reduction at Day 54 in the 48 mg cohort.
- Participants achieved a mean body-weight reduction of 6.1% at Day 26 (p < 0.05 vs placebo).
- Waist circumference was reduced by 5.8 cm at Day 26 and 9.8 cm at Day 54 (p < 0.05 vs placebo).
- Controlled attenuation parameter (CAP) reduced by -20.0 dB/m in the 48 mg group vs +24.0 dB/m with placebo.
- Liver stiffness improved by -10.3% from baseline by VCTE vs +13.8% with placebo.
- DA-1726 was generally well tolerated up to the 48 mg dose, with no serious adverse events.
- Ongoing Phase 1 Part 3a/3b titration studies continue to evaluate extended treatment at higher doses.
Price Impact
More from MTVA